Bioavailability of Chlorogenic and Phenolic Acids From Soluble Coffees

Coffee contributes to a large extent to our daily intake of phenolic compounds which have been associated with potential health benefits. A study by Richelle et al. (2001), using an LDL oxidation assay, showed that phenolic compounds in coffee possessed antioxidant activity which varied depending on the coffee bean source and the degree of roasting. Little is known about the bioavailability of phenolic compounds from coffee at various roasting degrees. Therefore, further human studies are required in order to demonstrate the absorption, and bioavailability of metabolites that may also be efficient in vivo.

The main objective of this clinical trial is to investigate the possible difference in the bioavailability of chlorogenic and phenolic acids from coffee at various roasting levels.

Study Overview

• Status: Completed
• Conditions: Healthy
• Intervention / Treatment: Other: Coffee bioavailability trial

Detailed Description

Coffee contributes to a large extent to our daily intake of phenolic compounds which have been associated with potential health benefits. A study by Richelle et al. (2001), using an LDL oxidation assay, showed that phenolic compounds in coffee possessed antioxidant activity which varied depending on the coffee bean source and the degree of roasting. Little is known about the bioavailability of phenolic compounds from coffee at various roast levels. Therefore, further human studies are required in order to demonstrate the absorption, and bioavailability of metabolites that may also be efficient in vivo.

The main objective of this clinical trial is to investigate the possible difference in the bioavailability of chlorogenic and phenolic acids from coffee at different roast levels.

After medical examination and approval, subjects will be randomly assigned to one of the four coffee treatments. Each study period correspond to the ingestion of one the treatments and study periods are separated by a one week washout period. Blood will be taken as a time course for 24h while urine will be collected for 30h. Investigators are also blinded with respect to the dose and the treatment given to the subjects.

• Study Type: Interventional
• Enrollment (Actual): 14
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Switzerland
  • Vaud
    • Lausanne 26, Vaud, Switzerland, 1000
      • NESTEC/Clinical Development Unit / Metabolic Unit

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 20 years to 60 years (Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• 20 - 60 years, male and female
• healthy as determined by the medical questionnaire and the medical visit
• normal weight: BMI 19 - 25
• Coffee drinkers with an average consumption of 2-5 cups per day
• having given informed consent

Exclusion Criteria:

• Intestinal or metabolic diseases / disorders such as diabetic, renal, hepatic, hypertension, pancreatic or ulcer
• food allergy
• Have had a major gastrointestinal surgery
• Difficulty to swallow
• Have a regular consumption of medication
• Have taken antibiotic therapy within the last 6 months
• Alcohol consumption > 2 units a day
• Smokers > 5 cigarettes a day
• Have given blood within the last 3 weeks before the start of the study
• Volunteers who cannot be expected to comply with treatment
• Currently participating or having participated in another clinical trial during the last 3 weeks

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: Quadruple

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Soluble coffee 1	Other: Coffee bioavailability trial; Coffee bioavailability trial
Experimental: Soluble coffee 2	Other: Coffee bioavailability trial; Coffee bioavailability trial
Experimental: Soluble coffee 3	Other: Coffee bioavailability trial; Coffee bioavailability trial
Experimental: Soluble coffee 4	Other: Coffee bioavailability trial; Coffee bioavailability trial

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Composite of pharmacokinetics: sum of AUC of chlorogenic and phenolic acids the of extreme treatments.	18 months

Secondary Outcome Measures

Outcome Measure	Time Frame
Composite of pharmacokinetics: AUC, Sum of AUC, Cmax, Tmax and T1/2 of plasma chlorogenic and phenolic acids from the other treatments.	18 months

Collaborators and Investigators

• Sponsor: Nestlé
• Investigators: Principal Investigator: Maurice Beaumont, MD, Ph.D, Nestlé

Study record dates

Study Major Dates

• Study Start: November 1, 2010
• Primary Completion (Actual): June 1, 2011
• Study Completion (Actual): June 1, 2013

Study Registration Dates

• First Submitted: July 21, 2011
• First Submitted That Met QC Criteria: July 21, 2011
• First Posted (Estimate): July 22, 2011

Study Record Updates

• Last Update Posted (Estimate): May 22, 2014
• Last Update Submitted That Met QC Criteria: May 21, 2014
• Last Verified: May 1, 2014

More Information

Terms related to this study

• Other Study ID Numbers: 10.04.Met